Home LiteratureArticle Details
PMID: 11520803 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1).

Blood ·Vol. 98 ·No. 5 ·2001-09-01 ·Pages 1524-31

Barata JT, Cardoso AA, Nadler LM, Boussiotis VA

Abstract

In normal T-cell development interleukin-7 (IL-7) functions as an antiapoptotic factor by regulating bcl-2 expression in immature thymocytes and mature T cells. Similar to what occurs in normal immature thymocytes, prevention of spontaneous apoptosis by IL-7 in precursor T-cell acute lymphoblastic leukemia (T-ALL) cells correlates with up-regulation of bcl-2. IL-7 is also implicated in leukemogenesis because IL-7 transgenic mice develop lymphoid malignancies, suggesting that IL-7 may regulate the generation and expansion of malignant cells. This study shows that in the presence of IL-7, T-ALL cells not only up-regulated bcl-2 expression and escaped apoptosis but also progressed in the cell cycle, resulting in sequential induction of cyclin D2 and cyclin A. Down-regulation of p27kip1 was mandatory for IL-7-mediated cell cycle progression and temporally coincided with activation of cyclin-dependent kinase (cdk)4 and cdk2 and hyperphosphorylation of Rb. Strikingly, forced expression of p27kip1 in T-ALL cells not only prevented cell cycle progression but also reversed IL-7-mediated up-regulation of bcl-2 and promotion of viability. These results show for the first time that a causative link between IL-7-mediated proliferation and p27kip1 down-regulation exists in malignant T cells. Moreover, these results suggest that p27kip1 may function as a tumor suppressor gene not only because it is a negative regulator of cell cycle progression but also because it is associated with induction of apoptosis of primary malignant cells.

MeSH Terms
Apoptosis/drug effects Cell Cycle/drug effects Cell Cycle Proteins/biosynthesis,genetics Cell Survival/drug effects Cyclin-Dependent Kinase Inhibitor p27 Cyclin-Dependent Kinases/biosynthesis,genetics Cyclins/biosynthesis,genetics Depression, Chemical Gene Expression Regulation, Leukemic/drug effects Genes, Tumor Suppressor Genes, bcl-2 Humans Immunophenotyping Interleukin-7/pharmacology Leukemia-Lymphoma, Adult T-Cell/pathology Neoplasm Proteins/biosynthesis,genetics Neoplastic Stem Cells/drug effects,metabolism Oligonucleotides, Antisense/pharmacology Proto-Oncogene Proteins c-bcl-2/biosynthesis,genetics Signal Transduction/drug effects Sirolimus/pharmacology Tumor Cells, Cultured Tumor Suppressor Proteins
Chemicals
Cell Cycle Proteins Cyclins Interleukin-7 Neoplasm Proteins Oligonucleotides, Antisense Proto-Oncogene Proteins c-bcl-2 Tumor Suppressor Proteins Cyclin-Dependent Kinase Inhibitor p27 Cyclin-Dependent Kinases Sirolimus
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Barata J T
Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Cardoso A A
Nadler L M
Boussiotis V A
Article Info
Journal
Blood
Abbr.
Blood
ISSN
0006-4971
Published
2001-09-01
Pages
1524-31
Language
English
Region
United States
NLM ID
7603509
Subset
IM
Grants
NIAID NIH HHS · AI 41584 · United States
NIAID NIH HHS · AI 43552 · United States
NCI NIH HHS · CA 68484 · United States
NHLBI NIH HHS · HL 54785 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com